Date: 2014-03-14
Type of information: Production agreement
Compound: manufacturing platform suite
Company: Alvotech (Iceland) Finesse Solutions (USA)
Therapeutic area:
Type agreement: manufacturing
production
Action mechanism:
Disease:
Details: * On March 14, 2014, Alvotech, a new player in the field of biopharmaceuticals and Finesse Solutions have announced that they have entered into a partnership that will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory® GMP manufacturing platform suite. SmartFactory® is a single-use cGMP bio-manufacturing capacity, which will allow Alvotech to rapidly expand its biosimilars business. Finesse’s customers will benefit from unprecedented access to Alvogen’s commercial, FDA approved, biomanufacturing facility. The first manufacturing suite will be in place by the end of 2015.
Financial terms:
Latest news:
